QC
RARE icon

Quent Capital’s Ultragenyx Pharmaceutical RARE Stock Holding History

Quent Capital’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.58K Buy
167
+123
+280% +$3.06K ﹤0.01% 1340
2026
Q1 		$922 Sell
44
-112
-72% -$2.52K ﹤0.01% 1445
2025
Q4 		$3.59K Sell
156
-60
-28% -$1.97K ﹤0.01% 1320
2025
Q3 		$6.5K Buy
+216
New +$6.48K ﹤0.01% 1098
2025
Q2 		– Sell
-183
Closed -$6.63K – 1018
2025
Q1 		$6.63K Sell
183
-14
-7% -$582 ﹤0.01% 969
2024
Q4 		$8.29K Sell
197
-29
-13% -$1.44K ﹤0.01% 964
2024
Q3 		$12.6K Hold
226
– – ﹤0.01% 974
2024
Q2 		$9.29K Buy
226
+14
+7% +$598 ﹤0.01% 1001
2024
Q1 		$9.9K Buy
212
+77
+57% +$3.63K ﹤0.01% 1021
2023
Q4 		$6.46K Sell
135
-54
-29% -$2.09K ﹤0.01% 1035
2023
Q3 		$6.74K Sell
189
-47
-20% -$1.86K ﹤0.01% 1003
2023
Q2 		$10.9K Hold
236
– – ﹤0.01% 919
2023
Q1 		$9.46K Hold
236
– – ﹤0.01% 930
2022
Q4 		$10.9K Buy
+236
New +$9.28K ﹤0.01% 880

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Quent Capital's RARE Position: Q2 2026 in Review

Quent Capital increased its Ultragenyx Pharmaceutical (RARE) stake by 280% in Q2 2026, buying an estimated $3.06K and bringing the position to 167 shares worth $5.58K. The position accounts for ﹤0.01% of the portfolio, ranked #1340.

Quent Capital first reported a position in RARE in Q4 2022 and has held it in 14 quarters since. The position peaked at $12.6K in Q3 2024. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Quent Capital held 167 shares of Ultragenyx Pharmaceutical worth $5.58K as of Q2 2026.
  • Quent Capital bought 123 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $3.06K.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Quent Capital's portfolio in Q2 2026, its #1340 holding.
  • Quent Capital first reported a position in Ultragenyx Pharmaceutical in Q4 2022 and has held it in 14 quarters since.
  • Quent Capital's Ultragenyx Pharmaceutical position peaked at $12.6K in Q3 2024.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Quent Capital's 13F filing for Q2 2026, filed 7 Aug 2026.